Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus
Author:
Publisher
Wiley
Subject
Virology,Infectious Diseases,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2009.01160.x/fullpdf
Reference22 articles.
1. Hepatitis B virus infection-natural history and clinical consequences;Ganem;N Engl J Med,2004
2. Chronic hepatitis B: update of recommendations;Lok;Hepatology,2004
3. Hepatitis B virus infection;Dienstag;N Engl J Med,2008
4. A one-year trial lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group;Lai;N Engl J Med,1998
5. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants;Chen;J Hepatol,2004
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties;Fused Pyrimidine-Based Drug Discovery;2023
2. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy;Therapeutic Apheresis and Dialysis;2019-07-15
3. In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue;Digestive Diseases and Sciences;2019-07-06
4. Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B;YAKUGAKU ZASSHI;2019-04-01
5. Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?;Drug Design, Development and Therapy;2019-04
Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3